Covidien
To see an up-to date selection of historical analyses and insights on
Covidien,
visit our
new, dynamically updated Company Summary report pages for Covidien.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Covidien are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Covidien,
or on any other Company covered by EvaluatePharma® Contact Us today.
PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
|
|
Rank |
Product |
Therapeutic Category |
Therapeutic Subcategory |
Pharmacological Class |
Phase (Current) |
| Covidien |
- |
Divalproex Sodium |
Central Nervous System |
Anti-epileptics |
GABA agonist |
Filed |
|
|
- |
Radionuclide Therapy |
Various |
Diagnostic imaging |
Radiodiagnostic agent |
Research project |
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| Covidien |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
| Market Capitalisation |
18,496 |
18,496 |
| PE Ratio (diluted) - Normalised (x) |
15.3 |
12.7 |
|
|
| Valuing the Enterprise |
| Enterprise Value |
20,293 |
20,293 |
| Free Cash Flow (Pre-Dividends) |
2,182 |
885 |
| FCF Yield (%) |
10.8% |
4.4% |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
9,535 |
8,313 |
| Cost of Goods Sold |
(4,835) |
(4,012) |
| S,G & A |
(2,325) |
(1,986) |
| R&D |
(232) |
(248) |
| Other Income/ Expense - Net |
(248) |
(13) |
| EBIT - Normalised |
1,895 |
2,054 |
| Net Interest & Financial Items |
(166) |
(139) |
| Pre-tax Profits - Normalised |
1,729 |
1,915 |
| Exceptionals |
(5) |
(15) |
| Income Before Taxes |
1,724 |
1,900 |
| Tax |
(531) |
(470) |
| Tax Rate (%) |
30.8% |
24.7% |
| Discontinued Items |
(158) |
(275) |
| Net Income - Reported |
1,035 |
1,155 |
| Net Income - Normalised |
1,196 |
1,441 |
|
|
| Per Share Data |
| EPS - Diluted |
2.08 |
2.32 |
| EPS - Basic |
2.08 |
2.32 |
| EPS - Normalised (diluted) |
2.41 |
2.90 |
| EPS - Normalised (basic) |
2.41 |
2.90 |
| Avg. Shares Outstanding - Diluted |
497.0 |
497.0 |
| Avg. Shares Outstanding - Basic |
497.0 |
497.0 |
| DPS |
0.00 |
0.00 |
|
|
|
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| Covidien Introduces 'Trusted Hands'
|
(Covidien)
|
12-Jan-2009 |
| Covidien Receives FDA Clearance to Market SILS(TM) Port Multiple Instrument Access Port
|
(Covidien)
|
08-Jan-2009 |
| EPIX Pharmaceuticals Announces FDA Approval of Vasovist® (gadofosveset trisodium)
|
(EPIX Pharmaceuticals)
|
22-Dec-2008 |
| FDA Clears Covidiens Evident Microwave Ablation System for Use in Nonresectable Liver Tumor Ablation
|
(Covidien)
|
19-Dec-2008 |
| Covidien Launches RapidVac(TM) Smoke Evacuator
|
(Covidien)
|
18-Dec-2008 |
| Covidien Completes Transition to New and Improved Magellan Safety Needle
|
(Covidien)
|
17-Dec-2008 |
| Covidien Launches Improved Magellan Safety Hypodermic Needle
|
(Covidien)
|
19-Nov-2008 |
| New Study Shows Subglottic Secretions Drainage Reduces Ventilator Associated Pneumonia and Antibiotic Use
|
(Covidien)
|
11-Nov-2008 |
| Covidien Introduces Versaport(TM) Plus Bladeless Trocars to Surgical Markets Globally
|
(Covidien)
|
15-Oct-2008 |
| Covidien Launches Parietex ProGrip(TM) Hernia Repair Mesh
|
(Covidien)
|
14-Oct-2008 |
| Covidien Introduces Permacol(TM) Biologic Implant
|
(Covidien)
|
09-Oct-2008 |
| Covidien Introduces the SprayShield(TM) Adhesion Barrier System to the European Marketplace
|
(Covidien)
|
02-Oct-2008 |
| Covidien Announces FDA Approval for its Generic Myocardial Perfusion Imaging Kit
|
(Covidien)
|
23-Sep-2008 |
| Covidien Launches TussiCaps(R) Extended-Release Capsules
|
(Covidien)
|
17-Sep-2008 |
| Covidien Launches Evident(TM) Microwave Ablation System Offering Surgical Oncologists and Interventional Radiologists Fast, Efficient Tool to Ablate Soft Tissue
|
(Covidien)
|
04-Sep-2008 |
| Covidien Launches Contrast Delivery System with RFID
|
(Covidien)
|
28-Jul-2008 |
| Covidien Launches Optistar(TM) Elite(TM) Contrast Delivery System
|
(Covidien)
|
16-Jul-2008 |
| EPIX Pharmaceuticals Announces South Korean Approval of Vasovist(R)
|
(EPIX Pharmaceuticals)
|
10-Jul-2008 |
| EPIX Pharmaceuticals Announces Resubmission of New Drug Application for Vasovist(R)
|
(EPIX Pharmaceuticals)
|
01-Jul-2008 |
| Covidien Launches Sandman Info(TM) and Sandman Auto(TM) CPAP Devices in the United States
|
(Covidien)
|
05-Jun-2008 |
| Covidien Receives FDA Clearance to Market Single-Incision Laparoscopic Surgery (SILS(TM)) Kit
|
(Covidien)
|
20-May-2008 |
| Ambrilia Reports Positive Final Phase III Results for its Octreotide Formulation C2L
|
(Ambrilia Biopharma)
|
14-May-2008 |
| Covidien Introduces AbsorbaTack(TM) 5mm Hernia Fixation Device Featuring Absorbable Tacks in Europe
|
(Covidien)
|
13-May-2008 |
| FDA Approves Covidien Contrast Delivery System with RFID
|
(Covidien)
|
07-May-2008 |
| Covidien Introduces the VascuSeal(TM) Vascular Sealant System to the European Marketplace
|
(Covidien)
|
01-May-2008 |
| EPIX Pharmaceuticals Announces Positive Results From Re-Read of Vasovist(R) Phase 3 Images
|
(EPIX Pharmaceuticals)
|
23-Apr-2008 |
| Covidien Unveils the Next Generation in Advanced Surgery
|
(Covidien)
|
10-Apr-2008 |
| Covidien Launches Endo Clip(TM) III 5mm Clip Applier
|
(Covidien)
|
01-Apr-2008 |
| Covidien Launches Three Access Products in Europe for Advanced Minimally Invasive Procedures
|
(Covidien)
|
31-Mar-2008 |
| Covidien Introduces Three Access Products for Advanced Minimally Invasive Procedures
|
(Covidien)
|
04-Mar-2008 |
| Covidien Announces Tentative FDA Approval for Its Generic Myocardial Perfusion Imaging Kit
|
(Covidien)
|
27-Feb-2008 |
| Covidien Introduces Sandman Intro(TM) CPAP Device
|
(Covidien)
|
11-Feb-2008 |
| EPIX Pharmaceuticals Reaches Agreement with FDA on Protocol, Initiates Re-Read of Vasovist(TM) Phase 3 Images
|
(EPIX Pharmaceuticals)
|
31-Jan-2008 |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| Covidien |
Acetaminophen & Codeine Phosphate |
acetaminophen & codeine |
|
|
Albunex |
albumin |
|
|
Anafranil |
clomipramine |
|
|
Anatrast |
barium sulfate |
|
|
Anexsia |
acetaminophen & hydrocodone |
|
|
Atenolol |
atenolol |
|
|
Baricon |
barium sulfate |
|
|
Baro-Cat |
barium sulfate |
|
|
Baros |
sodium bicarbonate & tartaric acid |
|
|
Barosperse |
barium sulfate |
|
|
Bear-E-Yum GI |
barium sulfate |
|
|
Butalbital, Acetaminophen & Caffeine |
butalbital, acetaminophen & caffeine |
|
|
C2L |
octreotide acetate |
|
|
CEA-Scan |
arcitumomab |
|
|
CheeTah |
barium sulfate |
|
|
Conray |
iothalamate meglumine |
|
|
Cysto-Conray II |
iothalamate meglumine |
|
|
Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate & Amp Sulfate |
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate & amphetamine sulfate |
|
|
Dextroamphetamine Sulfate |
dextroamphetamine |
|
|
Digital HD |
barium sulfate |
|
|
Divalproex Sodium |
divalproex sodium |
|
|
Enhancer |
barium sulfate |
|
|
Entrobar |
barium sulfate |
|
|
Entrocel |
methylcellulose |
|
|
EntroEase |
barium sulfate |
|
|
Epi-C |
barium sulfate |
|
|
Flo-Coat |
barium sulfate |
|
|
Fluoxetine |
fluoxetine |
|
|
Gallium Citrate |
gallium Ga-67 citrate |
|
|
GastroMARK |
ferumoxsil |
|
|
Gatifloxacin |
gatifloxacin |
|
|
HD 200 PLUS |
barium sulfate |
|
|
HD 85 |
barium sulfate |
|
|
Hexabrix |
ioxaglate meglumine & ioxaglate sodium |
|
|
Hydrocet |
acetaminophen & hydrocodone |
|
|
Hydrocodone Bitartrate & Acetaminophen |
acetaminophen & hydrocodone |
|
|
Hydromorphone Hydrochloride |
hydromorphone |
|
|
Imager |
barium sulfate |
|
|
Indium Chloride |
indium In-111 chloride |
|
|
InterSource 103 |
palladium Pd-103 |
|
|
InterSource 125 |
iodine I-125 |
|
|
Intropaste |
barium sulfate |
|
|
Liqui-Coat HD |
barium sulfate |
|
|
Lorcet-HD |
acetaminophen & hydrocodone |
|
|
Magnacet |
acetaminophen & oxycodone |
|
|
MD-76R |
diatrizoate meglumine & diatrizoate sodium |
|
|
MD-Gastroview |
diatrizoate meglumine & diatrizoate sodium |
|
|
Medebar Plus |
barium sulfate |
|
|
Medescan |
barium sulfate |
|
|
Meperidine Hydrochloride |
meperidine |
|
|
Metformin Hydrochloride |
metformin |
|
|
Methadone Hydrochloride |
methadone |
|
|
Methadose |
methadone |
|
|
Methylin |
methylphenidate |
|
|
Methylphenidate Hydrochloride |
methylphenidate |
|
|
Morphine Sulfate |
morphine sulfate |
|
|
Myoview |
technetium Tc-99m tetrofosmin |
|
|
Naltrexone Hydrochloride |
naltrexone |
|
|
NeutroSpec |
technetium Tc-99m fanolesomab |
|
|
OctreoScan |
indium In-111 pentetreotide |
|
|
OptiMARK |
gadoversetamide |
|
|
Optiray |
ioversol |
|
|
Optison |
octafluoropropane |
|
|
Osteoscan |
technetium Tc-99m etidronate |
|
|
Oxycet |
acetaminophen & oxycodone |
|
|
Oxycodone & Acetaminophen |
acetaminophen & oxycodone |
|
|
Oxycodone ER |
oxycodone |
|
|
Oxycodone Hydrochloride |
oxycodone |
|
|
Pamelor |
nortriptyline |
|
|
Pemoline |
pemoline |
|
|
Phendimetrazine Tartrate |
phendimetrazine |
|
|
Phosphocol |
chromic phosphate P-32 |
|
|
Prepcat |
barium sulfate |
|
|
Promethazine Hydrochloride |
promethazine |
|
|
Propoxyphene Napsylate & Acetaminophen |
propoxyphene napsylate & acetaminophen |
|
|
ProstaSeed |
iodine I-125 |
|
|
Radionuclide Therapy |
- |
|
|
Restoril |
temazepam |
|
|
Ribavirin |
ribavirin |
|
|
Scan C |
barium sulfate |
|
|
Selenomethionine SE 75 |
Selenomethionine SE-75 |
|
|
Sodium Chromate |
sodium chromate Cr-51 |
|
|
Sodium Iodide (I-123) |
sodium iodide I-123 |
|
|
Sodium Iodide (I-131) |
sodium iodide I-131 |
|
|
Sodium Phosphate |
sodium phosphate P-32 |
|
|
Sonazoid |
perflubutane |
|
|
Technescan DTPA |
technetium Tc-99m pentetate |
|
|
TechneScan Gluceptate |
technetium Tc-99m gluceptate |
|
|
TechneScan HDP |
technetium Tc-99m oxidronate |
|
|
Technescan MAA |
technetium Tc-99 albumin |
|
|
TechneScan MAG3 |
technetium Tc-99m mertiatide |
|
|
TechneScan PYP |
technetium Tc-99m pyrophosphate |
|
|
TechneScan Q12 |
technetium Tc-99m furifosmin |
|
|
Technetium Tc 99m Sestamibi |
technetium Tc-99m sestamibi |
|
|
Technetium Tc-99m Medronate |
technetium Tc-99m medronate |
|
|
Thallous Chloride |
thallous Tl-201 chloride |
|
|
Tofranil |
imipramine |
|
|
Tofranil-PM |
imipramine pamoate |
|
|
Tomocat |
barium sulfate |
|
|
Tonopaque |
barium sulfate |
|
|
Tramadol Hydrochloride |
tramadol |
|
|
Tridrate |
magnesium citrate |
|
|
Tussicaps |
chlorpheniramine polistirex & hydrocodone polistirex |
|
|
Tussizone-12 RF |
carbetapentane & chlorpheniramine |
|
|
UltraTag |
technetium Tc-99m |
|
|
Vasovist |
gadofosveset |
|
|
Warfarin Sodium |
warfarin sodium |
|
|
Xenon |
xenon XE-133 |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
